Vercaigne Lavern M, Collins David M, Penner S Brian
Faculty of Pharmacy, University of Manitoba, 50 Sifton Road, Winnipeg, Manitoba, Canada.
J Clin Pharmacol. 2005 Aug;45(8):895-900. doi: 10.1177/0091270005278808.
The purpose of this study was to compare erythropoietin dosage requirements during subcutaneous versus intravenous administration in a hemodialysis population. Hemodialysis patients receiving subcutaneous epoetin alfa were switched to the intravenous route using a prospective, crossover design. Baseline anemia parameters were measured at months -2, -1, and 0 when patients were receiving subcutaneous dosing and compared to months 4, 5, and 6 after the switch to intravenous dosing. Ninety-eight patients were enrolled into the study with an average age of 54.8 years. Over the course of the study, 34 patients were excluded from analysis, leaving 64 patients with complete hemoglobin and erythropoietin dosing data throughout the subcutaneous and intravenous evaluation periods. In these patients, the dose of erythropoietin increased significantly from the subcutaneous to the intravenous period (7567.7 to 10229.2 IU/wk). The conversion of hemodialysis patients from the subcutaneous to the intravenous route of administration significantly increased epoetin alfa dosage requirements.
本研究的目的是比较血液透析人群皮下注射与静脉注射促红细胞生成素时的剂量需求。接受皮下注射阿法依泊汀的血液透析患者采用前瞻性交叉设计转换为静脉注射途径。在患者接受皮下给药的第-2、-1和0个月测量基线贫血参数，并与转换为静脉给药后的第4、5和6个月进行比较。98名患者纳入研究，平均年龄54.8岁。在研究过程中，34名患者被排除在分析之外，剩下64名患者在整个皮下和静脉评估期有完整的血红蛋白和促红细胞生成素给药数据。在这些患者中，促红细胞生成素的剂量从皮下给药期到静脉给药期显著增加（从7567.7 IU/周增至10229.2 IU/周）。血液透析患者从皮下给药途径转换为静脉给药途径显著增加了阿法依泊汀的剂量需求。
